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Perceptions and Challenges Experienced by African
Physicians When Prescribing Methotrexate for Rheumatic
Disease: An Exploratory Study
Carol A. Hitchon,1
Girsh M. Mody,2 Candace H. Feldman,3
Yan Lau,4 Steven Shi,5 Michele Meltzer,6
4
3
4
Rosie Scuccimarri, Michael E. Weinblatt, and Ines Colmegna
Objective. Guidelines for methotrexate (MTX) use in rheumatic disease may not be feasible for physicians
practicing in the least developed countries. We aimed to understand the experiences of MTX prescribers relating
to MTX use for rheumatic disease in African countries to inform the development of culturally and geographically
appropriate recommendations.
Methods. African physicians who self-identified as MTX prescribers from countries classified as having a low
versus a medium or high Human Development Index (L-HDI versus MH-HDI) participated in semistructured interviews
between August 2016 and September 2017. Interviews were transcribed verbatim, coded thematically, and stratified
by HDI.
Results. Physicians (23 rheumatologists; six internists) from 29 African countries were interviewed (15 L-HDI;
14 MH-HDI). Identified barriers to MTX use included inconsistent MTX supply (reported by 87% L-HDI versus 43%
MH-HDI), compounded by financial restrictions (reported by 93% L-HDI versus 64% MH-HDI), patient hesitancy
based partly on cultural beliefs and societal roles (reported by 71%), few prescribers (reported by 33%), prevalent
infections (especially viral hepatitis, tuberculosis, and human immunodeficiency virus), and both availability and
cost of monitoring tests. MTX pretreatment evaluation and starting and maximal doses were similar between L-HDI
countries and MH-HDI countries.
Conclusion. The challenges of treating rheumatic disease in African countries include unreliable drug availability
and cost, limited subspecialists, and patient beliefs. Adapting recommendations for MTX use in the context of
prevalent endemic infections; ensuring safe but feasible MTX monitoring strategies, enhanced access to stable
drug supply, and specialized rheumatology care; and improving patient education are key to reducing the burden of
rheumatic diseases in L-HDI countries.
INTRODUCTION
Methotrexate (MTX) is considered standard of care for the
treatment of rheumatoid arthritis (RA) and has an important role
in the management of other rheumatic diseases (1). This relatively
low-cost disease-modifying agent is effective when appropriately

dosed, has versatile routes of administration, and has established safety profiles (2–
4). However, MTX has potential for
significant toxicity, including but not limited to hepatotoxicity, teratogenicity, and infection, especially with organisms targeted by
cell-mediated immunity (5). Clinical experience is required to use
MTX safely. Existing guidelines vary regarding recommendations
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SIGNIFICANCE & INNOVATIONS
• There are unique challenges in Africa regarding
methotrexate (MTX) use, including limited prescribers, high prevalence of endemic infections, inconsistent drug supply, and low health literacy of
patients.
• Cultural beliefs and financial limitations influence
MTX adherence.
• Regional guidelines for MTX need to address
screening for infections, strategies for affordable
and feasible monitoring and follow-up, consistent
access to the medication, and patient education.
for MTX prescribing and monitoring (6). Moreover, it is unknown
whether those guidelines are adequate to inform MTX use in
resource-poor regions (7).
The United Nations Human Development Program (UNDP)
ranks countries in four tiers according to the Human Development
Index (HDI; values between 0 and 1) (8). The HDI is a summary
index assessing health, education, and standard of living using
life expectancy at birth, expected years of schooling for children
and mean years of schooling for adults, and gross national income
per capita. Countries with very high development are those with an
HDI of 0.8 or more, whereas those with low development have an
HDI of less than 0.55. Countries with low socioeconomic development have high rates of poverty, experience greater economic
instability, and have limited human resources for health and education (9). According to the 2019 UNDP report, more than half
(58.5%) of all countries in Africa have low HDI (L-HDI) (10). Clinicians caring for rheumatology patients in Africa face multiple challenges. These include malnutrition, a high burden of infections, lack
of health personnel, and low health literacy (11–15). There are few
published studies on the screening, safety, and efficacy of MTX in
Africa to inform the development of guidelines for MTX use (16–20).
This study aimed to assess the experiences of MTX prescribers in African countries with different HDIs, to identify challenges
related to the use of MTX for rheumatic disease, and to highlight
priority management issues to consider when adapting existing
disease management guidelines to their environment.

PATIENTS AND METHODS
Participants. Physicians were identified on the basis
of membership in regional medical and rheumatology societies,
physician registries, and contact tracing (Supplementary Table 1).
Physicians (n = 80) were approached with an introductory email
outlining the purpose of the study, followed by a reminder email
if needed. Of the 50 respondents, all consenting physicians who
self-
identified as MTX prescribers were interviewed. Countries
were categorized based on the 2019 HDI, in which an HDI of less
than 0.55 is categorized as low (L-HDI), an HDI of 0.55 to 0.70 is
categorized as medium, and an HDI of more than 0.7 is classified
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as high human development. We also compared results using the
2015 HDI categories, which more closely reflect the years interviews took place (21).
Interviews. Semistructured phone interviews based on
a questionnaire (Supplementary Document) were conducted
between August 2016 and September 2017 by a single interviewer (IC) in English or French (according to the preference of the
interviewee) and audio-recorded (22). Interviews lasted between
45 minutes and 60 minutes. Data collected included demographic information of the interviewee, type of medical practice,
and estimated number of rheumatologists practicing in their
country. Participants were asked to describe their experiences
with the use of MTX specifically for the treatment of rheumatic
diseases, including screening practices, dosage of MTX, and use
of folic acid, and any barriers or challenges to prescribing MTX or
to patient adherence. Finally, participants were asked to describe
important considerations for future guideline development for
MTX use in their region. The interview content was expanded as
new concepts arose. Concept saturation (akin to study power)
was achieved. The interviews were transcribed verbatim, translated to English if needed, checked for accuracy, and entered
into DeDoose software (Sociocultural Research Consultants) for
qualitative analysis.
Analysis. The goals of the study analysis were to identify
themes related to MTX use, to see how they differed by HDI, and
to quantify different aspects of need to inform guideline development. Data from medium and high HDI (MH-HDI) countries were
combined because of the small number of interviews from high
HDI countries and thematic commonalities. Descriptive statistics
were used to compare demographics and medical practice patterns of participants from L-HDI and MH-HDI countries. Categorical variables are reported as number (percentage). Continuous
variables are reported as median (25th percentile-75th percentile).
As this study was exploratory and only one physician per country
was interviewed, we did not formally compare responses between
L-HDI and MH-HDI groups.
Qualitative analysis. Thematic analysis of the transcripts
was conducted separately by IC, CF, and CH in stages. First,
general concepts identified during the conduct of interviews were
explored. A pilot sample of four transcripts was independently
reviewed by CF and CH to identify the main themes and subthemes, develop a coding strategy, and ensure consistency
among reviewers. Themes were then applied to the complete set
of interviews. Additional themes were assessed as they arose.
Investigators reviewed and updated the thematic coding during the course of the analysis. Discrepancies were resolved by
consensus. Narrative synthesis summarized the theme content.
Representative quotes from participants in L-HDI and MH-HDI
countries were highlighted.
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Ethics. The study complies with the Declaration of Helsinki. It
was approved by the institutional ethics boards of the University of
Manitoba (H2016;020 and HS19277), McGill University (16-037),
and the University of KwaZulu-
Natal (BE376/16). Participants
provided verbal informed consent.

RESULTS
Between 2016 and 2017, 30 physicians from 29 African
countries were interviewed. In one L-HDI country, two interviews
were conducted, one with a trainee and one more informative
interview with a practicing physician; we excluded the trainee
interview. The countries represented were distributed across the
African continent and included 15/31 (48%), 8/13 (62%), and
6/9 (67%) of all low, medium, and high HDI countries based on
their 2019 HDI category (Figure 1). The demographics of the
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participants are shown in Table 1. Most participants were rheumatologists, were affiliated with a university or other academic
institution, and worked in the country’s capital city. The estimated
number of rheumatologists per country varied widely; however,
MH-
HDI countries tended to have more rheumatologists than
L-HDI countries (0-350 rheumatologists versus 0-15 rheumatologists). Four L-HDI countries and one MH-HDI country had no
practicing rheumatologist. In many countries, MTX was also prescribed by nonrheumatologists (82% of all countries; 93% L-HDI
versus 69% MH-
HDI). MTX prescribing practices were similar
between L-HDI and MH-HDI countries, with comparable dosing
targets and use of folic acid. Drug availability and cost (reported
by 82% of all countries; 93% L-HDI versus 64% MH-HDI) and
limited prescribers and monitoring capacity (reported by 33% of
all countries; 28% L-HDI versus 38% MH-HDI) were identified as
barriers to adherence (Table 2).

Figure 1. Countries participating in interviews. Shading indicates 2019 Human Development Index (HDI) category of country. Symbol identifies
countries participating in interviews.
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Table 1.
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Demographics of participants and rheumatology capacity

Rheumatologista
Male sex
Language of interview (English)
Official language of country
English
French
Arabic
Amharic
Years in practicea
Practise located in capital city
Main practice type
Hospital-based
University affiliate
Private
Treats adults and children
MTX prescribed by nonrheumatologists in countryb
Only rheumatology
Other prescriber
Internal medicine or medical subspecialties
Orthopedics
Generalists and medical officers

Total
(N = 29)

Low HDI
(n = 15)

Medium/High
HDI (n = 14)

23 (79)
20 (69)
17 (59)

11 (73)
12 (80)
6 (40)

12 (86)
8 (57)
11 (79)

13 (45)
10 (34)
5 (17)
1 (3)
8 (4-12)
18 (62)

4 (27)
9 (60)
1 (7)
1 (7)
8 (2.0-12.0)
11 (73)

9 (64)
1 (7)
4 (29)
0 (0)
6.5 (4.0-16.8)
7 (50)

3 (10)
24 (83)
2 (7)
23 (79)

1 (7)
14 (93)
0 (0)
14 (93)

2 (14)
10 (71)
2 (14)
9 (64)

5 (19)

1 (7)

4 (31)

19 (70)
4 (15)
2 (7)

11 (79)
1 (7)
1 (7)

8 (62)
3 (23)
1 (8)

Abbreviation: HDI, human development index (2019); MTX, methotrexate.
Categorical data are n (%); continuous data are median (25th percentile-75th percentile).
Years in practice were available for 11 low HDI countries and 12 medium/high HDI countries.
b
Prescriber status was missing for one low HDI country and one medium/high HDI country; total is
greater than 27 as it includes countries with multiple prescriber categories (internal medicine +
orthopedics [two medium/high HDI], orthopedics + generalists/house officers [one medium/high HDI],
and other specialists + generalists/house officers [one low HDI]).
a

Between 2015 and 2019, two countries (Cameroon and
Zimbabwe) changed from an L-HDI to an MH-HDI category.
Results were similar when the 2015 HDI definitions were
applied (Supplementary Tables 2 and 3).
Thematic analysis of interviews. The experiences
reported by the participants were grouped into the following
three main categories: 1) barriers to the use of MTX, including
drug availability, financial constraints, and patient hesitancy; 2)
human resources; and 3) patterns of MTX use, including comorbidity screening, dosing and monitoring, and family planning.
Representative quotes are presented below and in Supplementary Table 4.
Barriers to MTX use. Availability of MTX. The most significant barrier to the use of MTX for patients with rheumatic diseases was the lack of consistent access to the drug (for oral
MTX, 66% of all countries; 87% L-HDI versus 43% HM-HDI)
(Table 2). Country-wide shortages occurred often, and, when
supplies were limited, oncology patients received priority in
some countries. In L-HDI countries, the availability of oral MTX
outside of large centers was particularly problematic and was
believed to be related to limited prescribing; thus, pharmacies
did not maintain stock. In MH-HDI countries, supplies were generally more available when pharmacies were reminded to maintain stocks. Essentially, all countries reported limited availability

of parenteral MTX for rheumatic disease, although this was primarily for rural locations in MH-HDI countries. Some physicians
raised concerns regarding drug quality, particularly during times
of country-
wide stock limitations. These concerns primarily
referred to the source and composition of the imported drug. As
the use of MTX for rheumatic diseases increased, drug availability seemed to improve for some larger centers in MH-HDI countries. An L-HDI physician said “you feel like [methotrexate] can
run out of the store at any point in time…[lack of drug] is true for
any drug in this country…For rheumatic diseases…inconsistent
availability of drugs is a big big problem.” One physician also said
“methotrexate is one of the three main drugs used for cancer…
So when the country goes through some financial hardship…the
cancer patients will buy all what is available and the rheumatic
patients will not have.”
Financial restrictions. Financial restrictions further compounded limitations associated with drug access and monitoring, sometimes affecting drug prescribing. One L-HDI physician
stated “sometimes we just give [patients] hydroxychloroquine
and prednisone, which is cheaper.” Although many countries
had infrastructure in place to provide partial coverage for drug
costs, the costs were often prohibitive for those not covered.
For some patients from rural areas who were eligible to receive
drugs without payment, the cost of traveling to dispensing
sites was unaffordable. Similarly, costs of laboratory and imaging tests for screening and monitoring, when the responsibility
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Table 2. MTX prescribing patterns

Rheumatology indication for prescribing
Main condition rheumatoid arthritis
Secondary conditionsb
Connective tissue disease
Psoriatic arthritis
Juvenile idiopathic arthritis
Pre-MTX evaluation
Lung, liver, kidney, CBCb,c
Radiographs done
TB screen doned
HIV serologies done or available
Hepatitis B/C serologies done
Pregnancy screen by historyb
Alcohol counselling, no/NA/yes
MTX dose
Starting dose, mg/week
Maximum dose, mg/week
Folate prescribed
Prescribing challenges
Cost per month, US dollarse
Injectable formulation available
Inconsistent MTX supply
MTX available in hospital pharmacy
Adherence challengesb,f
Cost and drug availability
Lack of prescribers/monitoring ability
Patient belief/education/intolerance
Patient stigma (hand deformities)

Totala
(N = 29)

L-HDI
(n = 15)

MH-HDI
(n = 14)

29 (100)

15 (100)

14 (100)

12 (43)
12 (43)
4 (14)

7 (50)
5 (36)
2 (14)

5 (36)
7 (50)
2 (14)

28 (97)
17 (59)
18 (62)
16 (55)
15 (52)
24/28 (85)
2/17/10

14 (93)
9 (60)
10 (67)
8 (53)
7 (47)
12/14 (86)
2/9/4

14 (100)
8 (57)
8 (57)
8 (57)
8 (57)
12/14 (86)
0/8/6

10 (10-14)
25 (20-25)
24 (83)

10 (7.5-15.0)
20 (15-25)
13 (87)

10.0 (10.0-14)
25 (24-25)
11 (79)

17.5 (8.8-23.5)
16 (55)
19 (66)
16 (55)

17.0 (7.5-25.0)
8 (53)
13 (87)
4 (27)

20.0 (8.8-223.8)
8 (57)
6 (43)
12 (86)

23 (82)
9 (33)
20 (71)
14 (48)

14 (93)
4 (28)
10 (67)
9 (60)

9 (64)
5 (38)
10 (77)
5 (36)

Abbreviation: CBC, complete blood count; HDI, human development index (2019); HIV, human immunodeficiency
virus; L-HDI, low HDI; MH-HDI, medium or high HDI; MTX, methotrexate; NA, not applicable due to religion/restricted
alcohol access; TB, tuberculosis; US, United States of America.
Connective tissue disease includes lupus vasculitis scleroderma.
a
Categorical data are reported as n (%); continuous data are reported as median (25th percentile-75th percentile).
b
Available for 14 L-HDI and 14 MH-HDI countries only.
c
History, physical examination, and minimal basic laboratory studies done.
d
TB screen may include physical examination and chest radiograph (interferon γ release assay usually not available).
e
Estimated cost for MTX 10-15 mg/week in US dollars.
f
Main categories reported.

of the patient, were often not affordable. As a result, although
all physicians monitored for potential MTX toxicity, many indicated that it was not feasible to follow existing recommendations for comorbidity screening and laboratory monitoring. The
scope and frequency of tests were often reduced to decrease
costs. Although many physicians raised these concerns, financial barriers appeared most significant in L-HDI countries. The
disparity between public and private health care systems was
also raised with private medicine being “well equipped” and
public medicine being in a “severe case of disrepair with unbelievable shortages [of drugs, laboratory resources, and staff].”
An L-HDI physician said “like all other chronic diseases we
face, there are a lot of follow-up problems, because as long as
the population still remains poor…we have a good number of
patients who fail to follow the treatment properly. Not because
they do not want to, but maybe because they do not have
the means.” An MH-HDI physician said “[in my country about]
50% of people have health insurance but even when you have

health insurance…you have to buy the medicine first and then
you are reimbursed.”
Patient hesitancy. Identified patient factors impacting MTX
use, particularly in L-
HDI countries, included misconceptions
about the role of MTX for rheumatic disease, stigma relating to
chronic disease and deforming arthritis, and cultural preferences
for traditional healers and medicine (Table 2). Because MTX is
primarily used (and prioritized) for oncology patients, dispensing
pharmacists were often unfamiliar with the role of MTX in rheumatic disease, contributing to misinformation and medication
nonadherence. Reinforcement of the rationale for MTX use was
often required. In some regions, cultural influences contributing to
stigma associated with chronic disease, in particular with deformities and resultant functional impairment, were thought to affect
health-seeking behavior. In some social groups, the concept of
“chronic” disease was not culturally accepted, leading to inadequate patient follow-up, treatment nonadherence, and alternative
“immediate” solution seeking. Preferences for traditional healing
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and healers, combined with misattribution of chronic (deforming)
disease to religious or mystic forces, were perceived to lead to
delayed presentation to “Western medicine” clinics or nonadherence to prescribed medication (reported by 71%). Societal expectations regarding family roles also impacted the acceptance
of MTX, particularly for young women reluctant to accept contraception while on MTX. According to an L-DH physician,
“[the] number one challenge I have is trying to get the
patient to understand the use of this drug…when the
patients take their prescription to pharmacists outside
the hospital, [the pharmacists tell them] ‘do you have
cancer? Why the doctors prescribed this drug to you?’…
Because of the information they get especially from pharmacists outside of hospital, a lot of them might not want
to comply initially with the medication, because they may
feel it is the wrong medication.”
Another L-HDI physician said the following:
“…our African cultures, almost do not believe in chronic diseases. An illness must have treatment. When you tell the
patients that their disease has no treatment, that they have
to keep being followed…if the patient does not feel better,
very soon he will look for other medicines, traditional medicines, or he will see the pastor … to find a solution quickly.”
An L-HDI physician also said that
“[there is stigma] when you have deformities like rheumatoid
arthritis, there are people who have lost their jobs, there are
women who have lost their marriages, there are those who
have been dismissed from their society, they predict that
maybe it is a witchcraft…he can no longer use his hands…”
An MH-HDI physician reported that
“…a lot of patients consider it is a spiritual condition…and
they need to seek spiritual interventions…”
Human resources. The shortage of rheumatologists and
inadequate education and training of other medical practitioners on
caring for patients with rheumatic diseases was a significant barrier
in many L-HDI countries. In these countries, patients with rheumatic
diseases are managed by general internists, other specialists, or
family practitioners. Lack of formal education and exposure to rheumatology during medical school were cited as factors leading to
delayed recognition and referral of patients with rheumatic diseases
by primary care physicians. In cases in which MTX treatment was
initiated by primary care physicians, referring internists, or orthopedic surgeons, lack of confidence with prescribing and monitoring
MTX were considered factors implicated in overconservative dosing, leading to inadequate disease control. As a result, when seen
by rheumatology providers, most patients, particularly those from
rural areas, had advanced deforming disease.
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An L-HDI physician said “the biggest problem is human capital. There are very, very few [physicians] who are comfortable
prescribing or initiating methotrexate.” An MH-HDI physician said
“I have seen too many patients…who have been substandardly
treated.”
Several interviewees from L-HDI countries commented on the
need to improve rheumatology education. Establishing rheumatology training during medical school, implementing a rheumatology curriculum for residents in training, and supporting physicians
interested in obtaining formal rheumatology subspecialty training
were considered ways to enhance rheumatology capacity and
improve patient care. The need for improved rheumatology education for allied health care professionals, including nurses and
pharmacists, was also identified. In several countries, physicians
have identified an interest in pursuing rheumatology subspecialty
training; such training is currently provided only in a few African
countries. Participating in personal continuing medical education
activities, educating local faculty, and maintaining networks with
rheumatology colleagues across Africa were mentioned as strategies to increase rheumatology awareness.
Patterns of MTX use. Comorbidity screening. Interviewees were asked about the impact of infections on MTX prescribing. Tuberculosis (TB) was widely endemic. There was regional
variation in the prevalence of hepatitis B and C, human immunodeficiency virus (HIV), and, in some countries, parasitic infections.
TB screening was generally limited to clinical assessment; it was
believed that high exposure rates made Mantoux testing unreliable, and serology testing was not widely available. TB reactivation
was raised as a concern with MTX use. Practice patterns in the
setting of TB varied from withholding MTX to starting MTX during
or after completing TB treatment. In most settings where HIV
was endemic or highly prevalent, patients were screened prior
to referral or HIV testing was done as part of the rheumatology
workup. MTX prescription was generally deferred until HIV treatment and viral suppression were achieved. Viral hepatitis prevalence was considered higher in most countries compared with
Western or European countries, though the importance of hepatitis B versus hepatitis C varied and influenced screening practices. In general, MTX was held unless viral hepatitis was inactive
or treated (Supplementary Table 5). Although common, malaria
was not considered to be a barrier to MTX use, as it is easily treated. Practice patterns related to endemic infections were
affected by regional infection prevalence more than HDI status.
Similarly, the importance of alcohol use and related counselling
varied depending on local cultural and religious factors.
One L-HDI physician said “we are also overwhelmed by infectious conditions so there is a lot of emphasis on dealing with infectious conditions.” An MH-HDI physician said “we have different
diseases and different concerns compared to the West especially
regarding infectious diseases…it is mainly chronic infectious diseases like hepatitis, because [in my country] there is much more
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hepatitis B and C than in the Western world…We also have tuberculosis which is very high compared to in Europe.”
MTX dosing and monitoring. Practice patterns of dosing
MTX varied by prescribers but were generally similar between
L-HDI and MH-HDI countries, as was the use of folate. Patient
intolerance was cited as a common issue, and, at least according to some prescribers, acceptable disease control could
be maintained with relatively low doses. Several doctors believed
that an inability to obtain requested tests also contributed to lower MTX doses being prescribed, patient nonadherence, and patient noncompliance with follow-up clinic visits.
An L-HDI physician said “It is the minimal checkup that we
ask for, but sometimes we are faced with difficulties where the
patient may not be able to [pay for tests] …This is due to poverty
and also to the fact that there is no system of health insurance,
[patients] can no longer come back because of lack of means,
lack of medicines, lack of money and everything.” An MH-HDI
physician said “I do not follow thoroughly the Western recommendations [for screening and monitoring]…I am adopting a somewhat lightened outline.”
Family planning. Pre-MTX pregnancy screening was usually
by clinical history alone in both L-HDI and MH-HDI countries.
Most physicians counselled contraception; some also referred
to family clinics or gynecologists. Cultural and religious considerations related to family planning complicated discussions and,
in some regions, contraception was not formally prescribed, and
women were told to stop MTX at the earliest sign of pregnancy.
Approaches to family planning were similar for L-HDI and MH-
HDI countries. An L-HDI physician in a Muslim country said “this
is a sociocultural problem…contraception is somewhat not well
seen by women and men of childbearing age.”
Need for local adaptation of MTX prescribing recommendations. Finally, we asked about the perceived need for
regional MTX prescribing recommendations and important issues
those should address. There was a general consensus, particularly
among physicians in L-HDI countries, that regional recommendations for MTX use in rheumatic disease were needed. Recommendations need to address the use of MTX in the context of
infections, including TB, hepatitis B and C, HIV, and other endemic
infections. Recommendations about the scope and frequency of
investigations for monitoring MTX safety are critical and need to
incorporate local realities relating to restricted testing capacity and
cost. Recommendations should also address differential diagnoses given the high prevalence in Africa of conditions not usually
found in Western countries, such as infectious diseases with rheumatic manifestations and nutritional deficits. Although rheumatologists felt that MTX use is ideally directed by rheumatology, most
interviewees felt that adapted recommendations should also target internists, who provide the majority of rheumatology care in
some countries, and primary care providers and orthopedists to
facilitate referral and follow-up care.

HITCHON ET AL

DISCUSSION
African clinicians prescribing MTX for systemic rheumatic
diseases were faced with a range of unique challenges. Critical barriers include limited numbers of trained rheumatologists,
inconsistent access to oral or parenteral MTX for rheumatology
patients, uncertainty regarding best approaches for assessing
comorbidities and endemic infections, and patient-related sociocultural influences, combined with low medical literacy. These
barriers are compounded by severe financial limitations. Prescribers highlighted that existing international guidelines are often not
applicable, as they do not address the unique concerns faced by
African clinicians.
There remains a shortage of rheumatologists in Africa, especially in L-HDI countries (11,23). Some countries have few or no
certified practicing rheumatologists. As a result, nonrheumatologists with variable expertise in rheumatology assume responsibility
for rheumatology care in many countries. Strategies to increase
rheumatology capacity are being explored; however, rheumatology training programs are limited to a few African countries,
and thus potential trainees incur additional expenses that may
be prohibitive. Enhanced rheumatology education during medical training, combined with innovative and regionally appropriate
educational opportunities for practicing physicians, both nonrheumatology specialists and primary care providers, can bridge this
rheumatology clinician shortage (23–28).
Reliable access to MTX was identified as one of the biggest
challenges to providing rheumatology care. Most countries did
not have consistent access to MTX for patients with rheumatic
diseases. In some regions, even other conventional disease-
modifying antirheumatic drugs were not widely available. Limited
drug availability and poverty likely contribute to high rates of corticosteroid and nonsteroidal anti-inflammatory use even though
steroids pose a greater risk of side effects (17,29,30). Demand for
MTX in Africa will likely increase with greater awareness of chronic
rheumatic diseases, optimization of their treatment approaches,
and growing number of specialty-trained rheumatologists (31).
Solutions to address MTX access will vary by region and will likely
require multifaceted approaches engaging national and regional
governments to stabilize supply pathways and enhance safe drug
dispensing capacity. There is a global responsibility to advocate
for the availability of key drugs used in noncommunicable diseases such as RA; such advocacy could be modeled on similar
initiatives directed towards HIV or tuberculosis.
Additional challenges relate to the use of MTX in the setting
of endemic infections and safety-monitoring restrictions. Despite
regional variation in the prevalence of those infections, there was
a general consensus that existing guidelines on MTX prescribing
do not adequately contemplate these issues. This uncertainty is
compounded by a lack of local data on some of these aspects.
Many guidelines recommend screening for HIV and avoiding MTX
in the setting of active hepatitis B or C and untreated or latent TB

|

METHOTREXATE IN AFRICA -CHALLENGES

(6,32). However, there is no consensus regarding the duration of
TB treatment needed prior to starting MTX, the risk of isoniazid
hepatitis, or the use of MTX in the setting of treated HIV. Financial and logistical limitations affecting patients and health systems contributed to difficulty following existing recommendations
for monitoring. Innovative screening and monitoring strategies,
potentially incorporating point-of-care testing, may be one option
if feasible and economically viable (33).
Patient adherence is critical for medication effectiveness (3).
Many issues such as intolerance, though possibly compounded
by limited access to parenteral MTX and monitoring challenges,
were similar to those experienced by MTX users globally. Other
sociocultural considerations, notably societal roles related to
family planning and cultural beliefs regarding traditional healing,
were also felt to impact patient health-seeking behavior and
acceptance of MTX. These concerns must be considered when
developing and implementing regional recommendations for
prescribing MTX. Patient education regarding the role of MTX in
the management of rheumatic diseases is needed, and patient
engagement during the development of recommendations is
critical.
Strengths of this study include the broad regional representation of MTX prescribers based on geography and economic development. Participants were identified using multiple strategies, and
our interview sample encompassed physicians from low, medium,
and high HDI countries across the African continent; however, not
all regions were represented, and only the viewpoints of a sample of physicians prescribing MTX were captured. For regions
with many rheumatologists, the viewpoints expressed may not
represent the breadth of local experiences. Having only one
provider from each country limits our ability to understand variability by country; nevertheless, item saturation was reached
when pooling providers according to HDI. Regions with severe
rheumatology capacity limitations may not have been included;
such regions may have unique regional infrastructure challenges
or competing health priorities. Generalists, orthopedic surgeons,
and primary care providers are critical for the identification, referral, and, in many cases, local follow-up of rheumatology patients
and likely have unique perceptions, educational needs, and comfort levels regarding managing patients receiving MTX. Similarly,
allied health workers, including nursing and pharmacy workers,
play key roles in patient education and MTX prescribing (15). Further work is required to determine the needs of these providers.
Finally, we chose to stratify countries on the basis of the 2019 HDI,
thereby providing a broader reflection of each country’s current
development than economic indices alone with contemporary
HDI classifications. However, the HDI does not incorporate the
full breadth of factors affecting human development potential or
disparities within a region, which may be extreme, and interviews
were conducted in 2016 and 2017. Two L-HDI countries converted to medium HDI between the 2015 and 2019 HDI reports,
but this did not change the study findings.
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Because of the unique barriers for patients and providers
in African countries, there is a clear need for regional guidelines
addressing safe prescribing of MTX for rheumatic diseases (34).
Any adaptation of existing prescribing guidelines should include
recommendations for MTX use in the context of common endemic
infections and provide data-
driven but feasible, cost-
conscious
recommendations for monitoring safety. Locally derived data are
needed. Advocating for improved access to fundamental rheumatic
disease medications, including MTX, should be both a regional and
an international priority. Improved access to rheumatologists is critical and, given existing severe shortages, should be complimented
by increasing educational training to generalists, orthopedic surgeons, and primary care and allied health providers and improving
patient education. Organizations such as the International League
of Associations for Rheumatology, which includes the American
College of Rheumatology, have service to the global rheumatology community as one of their missions and could provide leadership for such initiatives (35,36). Although this study focused on
the experiences of African clinicians, these findings are applicable
to resource-limited regions worldwide, even to rural communities
in better resourced countries (37–39), and are increasingly relevant
to rheumatologists as international travel and globalization expand.
Initiatives addressing identified concerns can contribute to reducing health disparities in rheumatology care all over the world.
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